Casimersen: First Approval.

Area of Science:

• Biochemistry
• Genetics
• Pharmacology

Background:

• Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration.
• Current treatments aim to manage symptoms, but targeted therapies addressing the underlying genetic defect are crucial.
• Casimersen represents a novel therapeutic approach for a specific subset of DMD patients.

Purpose of the Study:

• To summarize the development milestones of casimersen, an exon-45 skipping antisense oligonucleotide.
• To detail the regulatory pathway leading to the US FDA accelerated approval of casimersen for DMD treatment.
• To provide an overview of the mechanism of action and clinical basis for casimersen's approval.

Main Methods:

• Development of casimersen, a phosphorodiamidate morpholino oligomer targeting DMD exon 45.
• Administration via intravenous infusion to facilitate exon skipping during mRNA processing.
• Clinical trials evaluating dystrophin protein production in skeletal muscle.

Main Results:

• Casimersen demonstrated an increase in dystrophin production in skeletal muscle of treated DMD patients.
• Achieved US FDA Accelerated Approval on February 25, 2021, for DMD patients with amenable mutations.
• Phase III development is ongoing globally, with continued approval pending confirmatory trials.

Conclusions:

• Casimersen is a promising targeted therapy for Duchenne muscular dystrophy, enabling functional dystrophin production.
• The accelerated approval highlights the potential of exon-skipping strategies in genetic disorders.
• Further clinical trials are essential to confirm the long-term efficacy and benefit of casimersen in DMD patients.